Response to Salvage Therapy in Patients Retreated After Failing or Relapsing From Fludarabine Regimens
| . | Fludarabine Retreatment CR + PR/Total (%) . | Other Treatment CR + PR/Total (%) . |
|---|---|---|
| Initial response | ||
| Overall | 13 + 28/63 (67) | 4 + 3/28 (25) |
| CR | 10 + 8/25 (72) | 1 + 0/4 (25) |
| PR-Nod | 3 + 13/23 (64) | 1 + 1/7 (28) |
| PR | 0 + 7/11 (70) | 0/5 (—) |
| Fail | 0/4 (—) | 2 + 2/12 (33) |
| Time to progression (CR, PR-Nod, PR) | ||
| <18 mo | 2 + 5/11 (64) | 0/8 (—) |
| 18-35.9 mo | 8 + 16/31 (77) | 2 + 1/5 (60) |
| ≥36 mo | 3 + 7/17 (59) | 0/3 (—) |
| Regimen | ||
| Fludarabine (3 or 5 days) | 8 + 18/35 (74) | |
| Fludara + Mitoxantrone | 0 + 3/9 (33) | |
| FLAP | 1 + 0/4 (25) | |
| Flud. + Ara-C + CDDP | 0/2 (—) | |
| Flud. + Cyclophosphamide | 4 + 7/13 (85) | |
| 2CDA | — | 0 + 1/2 (50) |
| CHOP | — | 2 + 2/7 (57) |
| Chlorambucil | — | 0/2 (—) |
| Allogeneic BMT | — | 2 + 0/4 (50) |
| VP-16 | — | 0/3 (—) |
| Taxol | — | 0/2 (—) |
| ASHAP | — | 0/1 (—) |
| Topotecan | — | 0/7 (—) |
| . | Fludarabine Retreatment CR + PR/Total (%) . | Other Treatment CR + PR/Total (%) . |
|---|---|---|
| Initial response | ||
| Overall | 13 + 28/63 (67) | 4 + 3/28 (25) |
| CR | 10 + 8/25 (72) | 1 + 0/4 (25) |
| PR-Nod | 3 + 13/23 (64) | 1 + 1/7 (28) |
| PR | 0 + 7/11 (70) | 0/5 (—) |
| Fail | 0/4 (—) | 2 + 2/12 (33) |
| Time to progression (CR, PR-Nod, PR) | ||
| <18 mo | 2 + 5/11 (64) | 0/8 (—) |
| 18-35.9 mo | 8 + 16/31 (77) | 2 + 1/5 (60) |
| ≥36 mo | 3 + 7/17 (59) | 0/3 (—) |
| Regimen | ||
| Fludarabine (3 or 5 days) | 8 + 18/35 (74) | |
| Fludara + Mitoxantrone | 0 + 3/9 (33) | |
| FLAP | 1 + 0/4 (25) | |
| Flud. + Ara-C + CDDP | 0/2 (—) | |
| Flud. + Cyclophosphamide | 4 + 7/13 (85) | |
| 2CDA | — | 0 + 1/2 (50) |
| CHOP | — | 2 + 2/7 (57) |
| Chlorambucil | — | 0/2 (—) |
| Allogeneic BMT | — | 2 + 0/4 (50) |
| VP-16 | — | 0/3 (—) |
| Taxol | — | 0/2 (—) |
| ASHAP | — | 0/1 (—) |
| Topotecan | — | 0/7 (—) |
Abbreviations: CHOP, cyclophosphamide + doxorubicin + vincristine + prednisone; FLAP, fludarabine + doxorubicin + prednisone; Ara-C, cytosine arabinoside; CDDP, cis-platinum; BMT, bone marrow transplantation.